Related Experiment Video
Updated: Feb 28, 2026
A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation
Published on: February 28, 2012
Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT
Valentina Kutyifa1, Christopher Beck2, Mary W Brown1
1Heart Research Follow-up Program of the Cardiology Division of the Department of Medicine, University of Rochester Medical Center, Rochester, NY.
Insights
Sudden cardiac death risk is high in diabetes patients post-myocardial infarction with preserved ejection fraction. The MADIT S-ICD study investigates if a subcutaneous implantable cardioverter defibrillator improves survival in these patients.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Background:
- Patients with diabetes mellitus and prior myocardial infarction, particularly older individuals with preserved left ventricular ejection fraction (LVEF), face a significant risk of sudden cardiac death.
- The subcutaneous implantable cardioverter defibrillator (S-ICD) offers a potentially favorable risk-benefit profile for managing this risk.
Purpose of the Study:
- To evaluate the survival benefit of the S-ICD in patients with diabetes mellitus following myocardial infarction and preserved LVEF (36%-50%).
- To test the hypothesis that S-ICD implantation reduces mortality in this specific high-risk population.
Main Methods:
- The MADIT S-ICD study is a clinical trial designed to assess the efficacy of S-ICD in a defined patient cohort.
- Inclusion criteria focus on diabetes, prior MI, older age, and LVEF between 36%-50%.
Main Results:
- This section is to be populated upon study completion.
Conclusions:
- This section is to be populated upon study completion.
Abstract:
Patients with diabetes mellitus, prior myocardial infarction, older age, and a relatively preserved left ventricular ejection fraction remain at risk for sudden cardiac death that is potentially amenable by the subcutaneous implantable cardioverter defibrillator with a good risk-benefit profile. The launched MADIT S-ICD study is designed to test the hypothesis that post-myocardial infarction diabetes patients with relatively preserved ejection fraction of 36%-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator.
